Form 4: Praxis CFO Kelly Reports Equity Awards and Tax Withholding

Praxis Precision Medicines CFO Timothy Kelly reports new restricted stock unit and stock option grants, alongside shares withheld for tax obligations.

Summary

• Timothy Edwin Kelly, Chief Financial Officer of Praxis Precision Medicines, Inc. (PRAX), reported several transactions related to his beneficial ownership.
• On January 8, 2026, Mr. Kelly was awarded 8,800 restricted stock units (RSUs), each representing a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs will vest in equal annual installments over a four-year period, commencing on January 8, 2027.
• Also on January 8, 2026, Mr. Kelly was granted 7,040 stock options with an exercise price of $294.38.
• The stock options vest over a four-year period, with 25% vesting on January 8, 2027, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• On January 10, 2026, 1,335 shares of Common Stock were withheld by the Issuer at a price of $288.45 per share to satisfy tax withholding obligations related to the vesting of previously reported restricted stock units.
• Following these transactions, Mr. Kelly's direct beneficial ownership of Common Stock is 31,989 shares, and he beneficially owns 7,040 stock options.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation, which are generally neutral in sentiment as they reflect standard operational practices rather than new strategic developments or financial performance.

Positives

• The award of 8,800 restricted stock units and 7,040 stock options to the Chief Financial Officer aligns management's interests with long-term shareholder value through equity incentives.

Negatives

• 1,335 shares of Common Stock were disposed of to cover tax withholding obligations, resulting in a reduction of direct beneficial ownership.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend over a four-year period, indicating a long-term incentive structure tied to the Chief Financial Officer's continued service.

Industry Context

The equity awards to the Chief Financial Officer are a standard practice in the biotechnology and pharmaceutical industry, aiming to incentivize executive retention and performance by aligning their financial interests with the company's long-term success.

Comparison to Industry Standards

• The structure of equity compensation, including restricted stock units and stock options with multi-year vesting schedules, is a common practice for executive compensation in the U.S. biopharmaceutical sector.
• The disposition of shares to cover tax withholding is a routine and expected event upon the vesting of equity awards, consistent with compensation practices across publicly traded companies.

Stakeholder Impact

• Shareholders: The equity awards align the CFO's interests with shareholder value, potentially fostering long-term growth.
• Employees: The compensation structure reflects standard executive incentive practices within the company.

Next Steps

• The restricted stock units will begin vesting in equal annual installments over a four-year period starting January 8, 2027.
• The stock options will begin vesting with 25% on January 8, 2027, and the remaining 75% in 36 equal monthly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (equity grants and tax-related share dispositions). Such transactions are standard and do not typically provide new information that would fundamentally alter the investment thesis or warrant a change in recommendation for the stock.

Keywords

Praxis Precision Medicines, PRAX, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, CFO Compensation, Equity Award, Tax Withholding